# Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

> **NCT02104830** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 135 (actual)

## Conditions studied

- Chemotherapy-induced Neutropenia

## Interventions

- **BIOLOGICAL:** Empegfilrastim 6 mg
- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Placebo №1
- **BIOLOGICAL:** Placebo №2
- **BIOLOGICAL:** Empegfilrastim 7.5 mg

## Key facts

- **NCT ID:** NCT02104830
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-06
- **Final completion:** 2014-10
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2016-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02104830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02104830, "Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02104830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*